AlphAIalphai — Financial news for AI agents
prnewswire.comAUG 241 min read$CAPR

Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR

Capricor Therapeutics (CAPR) faces a class action lawsuit for alleged securities violations. The DJS Law Group claims the company made false statements regarding its clinical data analysis and FDA agreement for Deramiocel. Shareholders who bought shares between December 17, 2025, and July 26, 2026, are encouraged to contact the firm by September 28, 2026, to discuss potential recovery.

Original reporting
prnewswire.com
Published Aug 24, 2026, 8:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 24, 2026, 8:11 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefRegulation
Primary signal
$CAPR
Bearish
medium confidence
Mentioned
$CAPR
Relevance
7/10
alphai data visualization · based on prnewswire.com
Decision brief

The 30-second read

$CAPRBearishLow
01

Why it matters

Legal action could trigger short interest and volatility in CAPR.

02

Market read

The lawsuit introduces new legal risk for CAPR, potentially affecting its share price.

03

What to watch

Potential settlement terms and impact on upcoming FDA filings.

Relevance 7/10Novelty 6/10Timing: deadline Sep 28 2026

Background

Press release from DJS Law Group soliciting class members for a securities fraud lawsuit.

Company-level read

Ticker impact

$CAPRBearishMedium confidence
Context

Capricor Therapeutics faces a class action lawsuit alleging false statements and securities law violations.

Expected impact

downside pressure pending lawsuit developments

Evidence & confidence

Legal exposure often leads to short-term sell pressure, especially for small-cap biotech.

Market effects

Sector

May raise scrutiny on biotech disclosure practices.

Regional

Limited to US biotech investors.

Global

Low global impact.

Counterpoint

What could challenge this read

If the lawsuit is dismissed, the stock could rebound.

Key entities

  • company
    Capricor Therapeutics, Inc.

    Biotech firm listed on NASDAQ (CAPR).

  • law_firm
    DJS Law Group

    Firm filing the class action on behalf of shareholders.

Read at source← All news

Related articles

AUG 21
$CAPRMed

/C O R R E C T I O N -- Kessler Topaz Meltzer & Check, LLP/

Capricor Therapeutics (CAPR) faces a securities fraud class action lawsuit for alleged misstatements about its lead product candidate's statistical analysis plan and FDA compliance. The lawsuit covers investments between December 17, 2025, and July 26, 2026, with a deadline to seek lead plaintiff status on September 28, 2026. The FDA's briefing documents revealed unapproved changes to the analysis plan, causing CAPR's stock to drop 64% on July 27, 2026.

prnewswire.com2 min
AUG 21
$CAPRLow

ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Contact Kessler Topaz Meltzer & Check, LLP

A class action lawsuit was filed against Capricor Therapeutics (NASDAQ: CAPR) by investors who purchased shares between December 17, 2025, and July 26, 2026. The lawsuit alleges securities fraud, claiming the company misrepresented its lead product candidate's statistical analysis plan and FDA compliance. The FDA's briefing documents revealed disagreements with Capricor's changes, causing the stock to drop 64%. Investors have until September 28, 2026, to seek lead plaintiff status.

prnewswire.com2 min
AUG 20
$CAPRLowAI 8/10

Capricor Therapeutics, Inc. Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit – Contact Kessler Topaz Meltzer & Check, LLP

A securities fraud class action lawsuit has been filed against Capricor Therapeutics (NASDAQ: CAPR) by investors who purchased shares between December 17, 2025, and July 26, 2026. The lawsuit alleges misstatements about the company's lead product candidate and FDA compliance. The stock dropped 64% on July 27, 2026, following FDA briefing documents. Investors have until September 28, 2026, to seek lead plaintiff status.

globenewswire.com2 min
AUG 20
$CAPRLow

CAPR Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Capricor Therapeutics Securities Lawsuit - Contact SueWallSt

Capricor Therapeutics (CAPR) faces a securities class action lawsuit after shares dropped 78.7% following FDA briefing documents and an advisory committee vote against its drug. Investors allege undisclosed changes to the statistical analysis plan. The class period is December 17, 2025, to July 26, 2026, with a lead plaintiff deadline of September 28, 2026.

prnewswire.com2 min
AUG 20
$CAPRMedAI 8/10

Capricor (CAPR) Closed 58% Higher on an FDA Lifeline. Is Approval Really Back on Track?

Capricor Therapeutics (CAPR) shares rose 58% to $6.65 after the FDA agreed to review 24-month data for its Duchenne muscular dystrophy treatment, deramiocel. The company plans to submit the data, potentially delaying the FDA's decision. CAPR remains 66% below its July 24 close after a regulatory setback. The FDA and advisory panel had raised concerns about the treatment's effectiveness and data analysis. CAPR had $237.9 million in cash as of June 30.

yahoo.com2 min
AUG 19
$CAPRMed

Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Capricor Therapeutics (CAPR) faces a class action lawsuit over alleged securities violations. The suit claims the company and executives failed to disclose material information between December 17, 2025, and July 26, 2026. The FDA criticized changes to the statistical analysis plan for Capricor's lead product, Deramiocel, causing the stock to drop 64% on July 27, 2026. Investors have until September 28, 2026, to join the lawsuit.

globenewswire.com2 min